Innovative trends in the design of therapeutic trials in psychopharmacology and psychotherapy

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 40, Issue 1, 2013, Pages 306-311

  Fava, Giovanni A ^a,b   Tomba, Elena ^a   Tossani, Eliana ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Psychopharmacology; Psychotherapy; Randomized controlled trials; Rating scales; Recovery; Sequential design

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CLOMIPRAMINE; FLUOXETINE; IMIPRAMINE; PAROXETINE; PLACEBO;

CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DISEASE MODEL; HUMAN; MEDICAL HISTORY; OBSESSIVE COMPULSIVE DISORDER; PANIC; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN; SYMPTOMATOLOGY; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; PSYCHOPHARMACOLOGY; PSYCHOTHERAPY; RESEARCH DESIGN;

EID: 84869485345     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.10.014     Document Type: Review

References (84)

1. Al Khalaf M.H., Thalib L., Doi S.A.R. Combining heterogeneous studies using the random-effects model is a mistake and leads to inconclusive meta-analyses. J Clin Epidemiol 2011, 64:119-123.
2. Antonovsky A. The structure and properties of the sense of coherence scale. Soc Sci Med 1993, 36:725-733.
3. Arfken C.L., Balon R. Declining participation in research studies. Psychother Psychosom 2011, 80:325-328.
4. Ball J.R., Kiloh L.G. A controlled trial of imipramine in treatment of depressive states. Br Med J 1959, ii:1052-1055.
5. Batstra L., Frances A. Holding the line against diagnostic inflation in psychiatry. Psychother Psychosom 2012, 81:5-10.
6. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide. J Clin Oncol 2003, 21:4165-4174.
7. Bech P. Measuring psychological distress and well-being. Psychother Psychosom 1990, 54:77-89.
8. Bech P. The struggle for subtypes in primary and secondary depression and their mode-specific treatment or healing. Psychother Psychosom 2010, 79:331-338.
9. Bech P., Gram L.F., Dein E., Jacobsen O., Vitger J., Bolwig T.G. Quantitative rating of depressive states. Acta Psychiatr Scand 1975, 51:161-170.
10. Belaise C., Gatti A., Chouinard V.A., Chouinard G. Patient online report of selective serotonin reuptake inhibitor-induced persistent post-withdrawal anxiety and mood disorders. Psychother Psychosom 2012, 81:386-388.
11. Belami C.P., Wany W., Johnson D.H., Wagner H., Schiller J., Veeder M., et al. Phase III study of the Eastern Cooperative Oncology Group (ECOG2597). J Clin Oncol 2005, 23:3760-3767.
12. Bockting C.L., Schene A.H., Spinhoven P., Koeter M.W., Wouters L.F., Huyser J., et al. Preventing relapse/recurrence in recurrent depression using cognitive therapy: a randomized controlled trial. J Consult Clin Psychol 2005, 73:647-657.
13. Bonsack C., Gibellini Manetti S., Favrod J., Montagrin Y., Besson J., Bovet P., et al. Motivational intervention to reduce cannabis use in young people with psychosis. Psychother Psychosom 2011, 80:287-297.
14. Borm G.F., Donders R. A treatment should be evaluated by small trials. J Clin Epidemiol 2009, 62:887-889.
15. Bradford Hill A. Memories of the British streptomycin trial in turberculosis. Control Clin Trials 1990, 11:77-79.
16. Collins L.M., Murphy S.A., Strecher V. The Multiphase Optimization Strategy (MOST) and the Sequential Multiple Assignment Randomized Trial (SMART). Am J Prev Med 2007, 32:S112-S118.
17. De Leon J. Evidence-based medicine versus personalized medicine. Are they enemies?. J Clin Psychopharmacol 2012, 32:143-164.
18. deGroot V., Beckerman H., Lankhorst G.J., Bouter L.M. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003, 56:221-229.
19. Downing R.W., Rickels K. Nonspecific factors and their interaction with psychological treatment in pharmacotherapy. Psychopharmacology: a generation of progress 1978, 1419-1428. Raven Press, New York. M.A. Lipton, A. Di Mascio, K.F. Killam (Eds.).
20. Fava G.A. Unmasking special interest groups. Psychother Psychosom 2010, 79:203-207.
21. Fava G.A. Statistical alchemy for drug treatment of generalized anxiety disorder: a commentary on the meta-analysis by Baldwin et al. (BMJ 2011; 342: d1199). Psychother Psychosom 2011, 80:261-263.
22. Fava G.A., Belaise C. A discussion of the role of clinimetrics and the misleading effects of psychometric theory. J Clin Epidemiol 2005, 5:753-756.
23. Fava G.A., Kellner R. Staging: a neglected dimension in psychiatric classification. Acta Psychiatr Scand 1993, 87:225-230.
24. Fava G.A., Offidani E. The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:1593-1602.
25. Fava G.A., Tomba E. New modalities of assessment and treatment planning in depression. CNS Drugs 2010, 24:453-465.
26. Fava G.A., Grandi S., Zielezny M., Canestrari R., Morphy M.A. Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994, 151:1295-1299.
27. Fava G.A., Grandi S., Zielezny M., Rafanelli C., Canestrari R. Four year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1996, 153:945-947.
28. Fava G.A., Savron G., Zielezny M., Grandi S., Rafanelli C., Conti S. Overcoming resistance to exposure in panic disorder with agoraphobia. Acta Psychiatr Scand 1997, 95:306-312.
29. Fava G.A., Rafanelli C., Grandi S., Conti S., Belluardo P. Prevention of recurrent depression with cognitive behavioral therapy. Arch Gen Psychiatry 1998, 55:816-820.
30. Fava M., Evins A.E., Dorer D.J., Schoenfeld D.A. The problem of the placebo response in clinical trials for psychiatric disorders. Psychother Psychosom 2003, 72:115-127.
31. Fava G.A., Ruini C., Rafanelli C., Finos L., Conti S., Grandi S. Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 2004, 161:1872-1876.
32. Fava G.A., Ruini C., Belaise C. The concept of recovery in major depression. Psychol Med 2007, 37:307-317.
33. Fava G.A., Guidi J., Semprini F., Tomba E., Sonino N. Clinical assessment of allostatic load and clinimetric criteria. Psychother Psychosom 2010, 79:280-284.
34. Fava G.A., Rafanelli C., Tomba E., Guidi J., Grandi S. The sequential combination of cognitive behavioral treatment and well-being therapy in cyclothymic disorder. Psychother Psychosom 2011, 80:136-143.
35. Fava G.A., Rafanelli R., Tomba E. The clinical process in psychiatry: a clinimetric approach. J Clin Psychiatry 2012, 73:173-184.
36. Fava M., Mischoulon D., Iosifescu D., Witte J., Pencina M., Flynn M., et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy (ADT) among depressed outpatients with inadequate response to prior ADT (ADAPT-A study). Psychother Psychosom 2012, 81:87-97.
37. Feinstein A.R. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis 1970, 23:455-468.
38. Feinstein A.R. The Jones criteria and the challenge of clinimetrics. Circulation 1982, 66:1-5.
39. Feinstein A.R. Clinimetrics 1987, Yale University Press, New Haven, CT.
40. Feinstein A.R. Meta-analysis: statistical alchemy for the 21st century. J Clin Epidemiol 1995, 48:71-79.
41. Feinstein A.R., Horwitz R.I. Problems in the "evidence" of "evidence-based medicine". Am J Med 1997, 103:529-535.
42. Gliedman C.H., Nash E.H., Imber S.D., Stone A.R., Frank J.D. Reduction of symptoms by pharmacologically inert substances and by short-term psychotherapy. AMA Arch Neurol Psychiatry 1958, 79:345-351.
43. Guidi J., Fava G.A., Picardi A., Porcelli P., Bellomo A., Grandi S., et al. Subtyping depression in the medically ill by cluster analysis. J Affect Disord 2011, 132:383-388.
44. Guidi J., Fava G.A., Bech P., Paykel E. The clinical interview for depression. Psychother Psychosom 2011, 80:10-27.
45. Hasan F., al-Khaldi J., Asker H., Varghese R., Siddique I., al-Shammali M., et al. Treatment of chronic hepatitis B with sequential administration of interferon and lamivudine. Hepatogastroenterology 2003, 50:2040-2042.
46. Holzgreve H. Combination versus monotherapy as initial treatment in hypertension. Herz 2003, 28:725-732.
47. Horwitz R.I., Singer B.H., Makuch R.W., Viscoli C.M. Can treatment that is helpful on average be harmful to some patients?. J Clin Epidemiol 1996, 49:395-400.
48. Husted J.A., Cook R.J., Farewell V.T., Gladmann D.D. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000, 53:459-468.
49. Jane-wit D., Horwitz R.I., Concato J. Variation in results from randomized, controlled trials: stochastic or systematic?. J Clin Epidemiol 2010, 63:56-63.
50. Jureidini J.N., McHenry L.B. Key opinion leaders and paediatric antidepressant overprescribing. Psychother Psychosom 2009, 78:197-201.
51. Kellner R. A symptom questionnaire. J Clin Psychiatry 1987, 48:269-274.
52. Kiloh L.G., Ball J.R., Garside R.F. Prognostic factors in treatment of depressive states with imipramine. Br Med J 1962, i:1225-1227.
53. Kuyken W., Byford S., Taylor R.S., Watkins E., Holden E., White K., et al. Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. J Consult Clin Psychol 2008, 76:966-978.
54. Lavori P.W., Dawson R. Adaptive treatment strategies in chronic disease. Annu Rev Med 2008, 59:443-453.
55. Lebwohl M., Menter A., Koo J., Feldman S.R. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol 2004, 50:416-430.
56. Lei H., Nahum-Shani I., Lynch K., Oslin D., Murphy S.A. A "SMART" design for building individualized treatment sequences. Annu Rev Clin Psychol 2012, 8:21-48.
57. Lichtenberg P., Belmaker R.H. Subtyping major depressive disorder. Psychother Psychosom 2010, 79:131-135.
58. Ma S.H., Teasdale J.D. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. J Consult Clin Psychol 2004, 72:31-40.
59. March J.S., Silva S., Petrycki S., Curry J., Wells K., Fairbank J., et al. Fluoxetine, cognitive behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 2004, 292:807-820.
60. Marks I. Fears, phobias and rituals 1987, Oxford University Press, New York.
61. Medical Research Council Streptomycin in Tuberculosis Trials Committee Streptomycin treatment for pulmonary tuberculosis. BMJ 1948, ii:769-782.
62. Otto M.W., Nierenberg A.A. Assay sensitivity, failed clinical trials, and the conduct of science. Psychother Psychosom 2002, 71:241-243.
63. Paykel E.S., Scott J., Teasdale J.D., Johnson A.L., Garland A., Moore R., et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999, 56:829-835.
64. Rickels K. Psychopharmacologic agents. J Nerv Ment Dis 1963, 136:540-549.
65. Robbins G.K., De Gruttola V., Shafer R.N., Smeaton L.M., Snyder S.W., Pettinelli C., et al. Comparison of sequential three-drug regimen as initial therapy for HIV-1 infection. N Engl J Med 2003, 349:2293-2303.
66. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps. Am J Psychiatry 2006, 163:1905-1917.
67. Ryff C.D. Happiness is everything, or is it?. J Pers Soc Psychol 1989, 6:1069-1081.
68. Sechrest L. Incremental validity: a recommendation. Educ Psychol Meas 1963, 23:153-158.
69. Sirri L., Grandi S. Illness behavior. Adv Psychosom Med 2012, 32:160-181.
70. Targum S.D., Pollack M.H., Fava M. Redefining affective disorders: relevance for drug development. CNS Neuroscience Therap 2008, 14:2-9.
71. Teasdale J.D., Segal Z.V., Williams J.M., Ridgeway V.A., Soulsby J.M., Lan M.A. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. J Consult Clin Psychol 2000, 68:615-623.
72. Tinetti M.E., Fried T. The end of the disease era. Am J Med 2004, 116:179-185.
73. Tinetti M.E., Bogardus S.T., Agostini J.V. Potential pitfalls of disease specific guidelines for patients with multiple conditions. N Engl J Med 2004, 351:2870-2874.
74. Tomba E. Nowhere patients. Psychother Psychosom 2012, 81:69-72.
75. Tomba E. Assessment of lifestyle in relation to health. Adv Psychosom Med 2012, 32:72-96.
76. Tomba E., Bech P. Clinimetrics and clinical psychometrics: macro- and micro-analysis. Psychother Psychosom 2012, 81:333-343.
77. Tomba E., Fava G.A. Treatment selection in depression: the role of clinical judgment. Psychiatr Clin North Am 2012, 35:87-98.
78. Tomba E., Rafanelli C., Grandi S., Guidi J., Fava G.A. Clinical configuration of cyclothymic disturbances. J Affect Disord 2012, 139:244-249.
79. Tossani E. The concept of mental pain. Psychother Psychosom in press; http://dx.doi.org/10.1159/000343003.
80. Uhlenhuth E.N., Rickels K., Fisher S., Park L.C., Lipman R.S., Mock J. Drug, doctor's verbal attitude and clinic setting in the symptomatic response to pharmacotherapy. Psychopharmacologia 1966, 9:392-418.
81. Vakil N., Vaira D. Sequential therapy for Helicobacter pylori. JAMA 2008, 300:1346-1347.
82. Vandenbroucke J.P. Benefits and harms of drug treatments. BMJ 2004, 329:2-3.
83. Wright J.G., Feinstein A.R. A comparative contrast of clinimetrics and psychometric methods for constructing indexes and rating scales. J Clin Epidemiol 1992, 45:1201-1218.
84. Zimmerman M. Symptom severity and guideline-based treatment recommendations for depressed patients: implications of DSM-5's potential recommendation of the PHQ-9 as the measure of choice for depression severity. Psychother Psychosom 2012, 81:329-332.